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Tuesday, February 5, 2013 403aextracellular domain (ECD) of CaSR with various spectroscopic methods in-
cluding the tryptophan fluorescence titration, circular dichroism (CD) and nu-
clear magnetic resonance (NMR) as well as molecular dynamic simulation.
These results provide important implications for our understanding of how
the CaSR integrates information about these two completely different classes
of agonists–an inorganic divalent cation, and another hand, a nutrient– how the
receptor senses these agonists in healthy and diseased states.
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Combretastatins, which are an important group of anticancer drugs,were iso-
lated by Pettit et al. from the African tree Combretum caffrum in 1989. Addi-
tionally, Liang et al. have reported that ten coumestans were isolated fromthe
roots of Hedysarum multijugum, which is a plant in Hedysarum Linn. of the
family Leguminosae used as a folk herbal drug in northwest China. Coumestans
comprise a class of naturally occurring products with a variety of biological ac-
tivities including phytoestrogenic, antibacterial, antifungal, antimyotoxic, and
phytoalexine effects. The anticancer properties of demethylwedelolactone
(DWEL) and wedelolactone (WEL), which are naturally occurring coumestans,
have not been well characterized. Due to their biological activities, the synthe-
sis of DWEL is achieved in which the longest linear sequence is only eight
steps in 38% overall yield from commercially available phloroglucinol. Furth-
more, the molecular model was examined the interactions of proteins and li-
gands as well. Finally, in this study, we investigated the anti-invasive effects
of synthetic WEL and DWEL on human MDA-MB-231 breast cancer cells.
We found that WEL and DWEL inhibited the anchorage-independent growth
and also suppressed cell motility and cell invasion of MDA-MB-231 cells. In
addition, WEL and DWEL reduced the activity and expression of matrix metal-
loproteinases (MMPs) involved in blocking the IkB-a/NFkB and MEK/ERK
signaling pathways in MDA-MB-231 cells. Furthermore, DWEL suppressed
the metastasis and lung colonization of the tumor cells in the nude mice. Alto-
gether, these data suggest that DWEL derivatives exert anti-invasive growth ef-
fect on breast cancer cells.
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Histone methyltransferases are enzymes that modify histone proteins via meth-
ylation of lysine or arginine residues. These epigenetic modifiers, such as
DOT1L and EZH2, have been found to play important roles in leukemogenic
processes.
Crystallographic and docking methods studied interactions within the DOT1L
binding site. Crystal structures of DOT1L also demonstrated variance in the
binding mode of ligands, possibly due to rearrangement in the DOT1L binding
site. We investigated this possibility by molecular dynamics (MD) simulations
and confirmed significant rearrangement of the substrate binding and activation
loops of DOT1L upon binding to competitive inhibitors. The druggability and
volume fluctuations of the binding pocket over time were determined.
The EZH2 methyltransferase is of interest due to its aberrant activity in many
cancers. Because there is no published crystal structure of EZH2, we used ho-
mology modeling with homologous proteins as templates. This model provides
structural information regarding the binding
modes of the S-adenosyl methionine (SAM)
cofactor and potential inhibitors of EZH2.
Through the synergistic combination of
in silico drug design, organic synthesis
and biochemical assays, our modeling ef-
forts for DOT1L and EZH2 will guide the
chemical syntheses of potent and selective
inhibitors of these enzymes.2071-Pos Board B90
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T cell receptors (TCRs) recognize peptides bound and presented by major his-
tocompatibility complex (MHC) proteins using multiple complementarity de-
termining region (CDR) loops. While numerous analyses have illuminatedstructural and biophysical aspects of TCR recognition, how the distribution
of binding free energy within TCR-pMHC interfaces promotes unique TCR
recognition features, including MHC restriction and the apparent dichotomy
of specificity and cross-reactivity, remains unclear. Utilizing double mutant cy-
cles, here we performed a comprehensive structural and thermodynamic decon-
struction of the interaction between the A6 TCR and the Tax peptide presented
by the class I MHC HLA-A2. In contrast with general expectations, we ob-
served that the central regions of the peptide and its interactions with the hyper-
variable CDR3 loops contribute little to specificity, instead promoting by
dynamic effects the cross-reactivity that is a hallmark of TCR recognition.
We also observed that TCR restriction towards HLA-A2 results from not
from conserved interactions with the germline loops, but instead from strong
interactions with the hypervariable CDR3 loop of the a chain. Formation of
these latter interactions, however, is dependent upon the unique structural prop-
erties of the peptide, highlighting that TCR specificity towards peptide and
MHC can emerge from the need to engage a unique, composite peptide/
MHC interface with tightly coupled structural properties.
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Multidrug (MD) (or xenobiotic) e,ux actively removes cytotoxic chemicals
from the interiors of normal-functioning cells. However, high levels of
e,ux can render drug-targeted cells resistant to a broad-range of therapeutic
agents, including those to which cells were never exposed. Key multidrug
resistance (MDR) contributors include allosteric e,ux pumps, gene regulators
and other sensory systems that mediate the detection and extrusion of diverse
drugs from cellular environments. To date, MDR functions remain only par-
tially understood. Ligand-dependent allosteric control in BmrR has been quan-
titatively addressed using in vitro transcription experiments, dose-response
curves and thermodynamic models that relate the observed transcriptional
responses to ligand binding and changes in BmrR conformation. Preliminary
results indicate that allosteric control in BmrR is sensitive to both energetic
and structural aspects of ligand recognition. Importantly, increased coopera-
tivity in signal control relative to recognition implicates a major allosteric
role for the RNA polymerase.
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Dihydropteroate synthase (DHPS) is an essential enzyme in the bacterial folate
biosynthetic pathway. It catalyzes the condensation of 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate (DHPP) with p-aminobenzoic acid (pABA) to
form the folate intermediate, 7,8-dihydropteroate. DHPS is the target of the
sulfonamide class of antibiotics. Widespread resistance to sulfonamides has de-
creased their clinical use. The active site of DHPS is comprised of three sub-
sites: the structured ‘‘pterin’’ site, the flexible pABA site, and the anion binding
pocket. Most of the drug resistant mutations have been mapped to the pABA
sub-site of DHPS. using an NMR ligand-based screening approach, a number
of structurally unrelated fragment-like small molecules have been identified
that inhibit the enzymatic activity of DHPS from Bacillus anthracis (Ba), Yer-
sinia pestis (Yp), and Staphylococcus aureus (Sa). Fragment hits were shown to
target the three sub-pockets of the active site and a novel site distinct from the
active site. The latter site potentially inhibits via an allosteric mechanism and
has been characterized by high resolution X-ray crystallography.
We screened the Maybridge Fragment library of 1,100 fragments using water
ligand observed gradient spectroscopy (waterLOGSY) as a primary screen
which resulted in a hit rate of 6.7 %. Of the 74 hits, 25 were shown to inhibit
DHPS activity using two independent enzyme activity assays. A total of eight
compounds inhibited the activity of DHPS from three different species (Ba, Yp,
and Sa). In addition to screening for inhibition, the fragment hits were validated
using a number of biophysical techniques including 2D NMR, SPR, competi-
tion waterLOGSY, and X-ray crystallography. Herein, we focus on two frag-
ment hits for which high-resolution x-ray crystal structures are available
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Photoreactive molecules like aryl azides play important role in life sciences,
as practical tools to achieve precisely timed covalent cross-links between li-
gands and targets. Since the azido group is small, stable and biologically inert,
